A new trading day began on Monday, with Compass Therapeutics Inc (NASDAQ: CMPX) stock price down -3.39% from the previous day of trading, before settling in for the closing price of $2.95. CMPX’s price has ranged from $0.87 to $4.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -104.70% over the past five years. Meanwhile, its annual earnings per share averaged -39.17%. With a float of $87.95 million, this company’s outstanding shares have now reached $138.28 million.
Let’s look at the performance matrix of the company that is accounted for 35 employees. In terms of profitability, gross margin is 100.0%, operating margin of -7273.41%, and the pretax margin is -6496.82%.
Compass Therapeutics Inc (CMPX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Compass Therapeutics Inc is 36.40%, while institutional ownership is 43.13%. The most recent insider transaction that took place on May 27 ’25, was worth 21,100. In this transaction CHIEF EXECUTIVE OFFICER of this company bought 10,000 shares at a rate of $2.11, taking the stock ownership to the 6,480,825 shares. Before that another transaction happened on Apr 09 ’25, when Company’s Director sold 3,571,428 for $1.59, making the entire transaction worth $5,678,571. This insider now owns 0 shares in total.
Compass Therapeutics Inc (CMPX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -39.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.37% during the next five years compared to -104.70% drop over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Here are Compass Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 463.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.40, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Compass Therapeutics Inc (NASDAQ: CMPX) saw its 5-day average volume 0.77 million, a negative change from its year-to-date volume of 1.39 million. As of the previous 9 days, the stock’s Stochastic %D was 10.93%.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 71.70%, which indicates a significant increase from 7.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was higher than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.64, while its 200-day Moving Average is $2.23.
